<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02724618</url>
  </required_header>
  <id_info>
    <org_study_id>406</org_study_id>
    <nct_id>NCT02724618</nct_id>
  </id_info>
  <brief_title>Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)</brief_title>
  <official_title>Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Behnam Daheshpour Charity Organization, Tehran, Iran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a growing body of evidence exploring the role of curcumin as a radioprotector
      against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor
      cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate
      cancer patients undergoing radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Actual">April 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proctitis [assessed using Common terminology criteria for adverse events (CTCAE)]</measure>
    <time_frame>90 days</time_frame>
    <description>Proctitis as assessed using Common terminology criteria for adverse events (CTCAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cystitis [assessed using CTCAE Grading Criteria]</measure>
    <time_frame>90 days</time_frame>
    <description>Cystitis as assessed using CTCAE Grading Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic Toxicity</measure>
    <time_frame>90 days</time_frame>
    <description>Hematologic Toxicity as assessed by significant reduction in hematologic components</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical progression-free survival (b-PFS)</measure>
    <time_frame>5-years</time_frame>
    <description>b-PFS as assessed using Prostate-Specific Antigen (PSA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Response</measure>
    <time_frame>3 months after treatment termination</time_frame>
    <description>Treatment Response as assessed using Magnetic Resonance Imaging techniques</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Curcumin plus RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120mg/day nanocurcumin during RT course</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo plus RT</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>120mg/day placebo of nanocurcumin during RT course</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>120mg/d oral nanocurcumin (3 capsules of SinaCurcumin速40 per day) 3 days before and during radiotherapy</description>
    <arm_group_label>Curcumin plus RT</arm_group_label>
    <other_name>SinaCurcumin速</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>RT</intervention_name>
    <description>EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT</description>
    <arm_group_label>Curcumin plus RT</arm_group_label>
    <arm_group_label>Placebo plus RT</arm_group_label>
    <other_name>External Beam Radiation Therapy (EBRT)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo (3 placebo capsules of SinaCurcumin速40 per day), 3 days before and during radiotherapy</description>
    <arm_group_label>Placebo plus RT</arm_group_label>
    <other_name>SinaCurcumin速 placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the prostate

          -  Candidate for External Beam Radiotherapy

          -  ECOG performance status 0-2

        Exclusion Criteria:

          -  Patients with Metastatic Prostate Cancer

          -  Patients with Kidney &amp; Liver dysfunction

          -  Gastrointestinal disorders such as IBD, reflux and peptic ulcers

          -  Any adverse reaction to curcumin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abolfazl Razzaghdoust</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shohada-e-Tajrish Medical Center</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2016</study_first_posted>
  <last_update_submitted>October 11, 2017</last_update_submitted>
  <last_update_submitted_qc>October 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Bahram Mofid</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Curcumin</keyword>
  <keyword>Protection, Radiation</keyword>
  <keyword>Controlled Clinical Trials, Randomized</keyword>
  <keyword>Radiation Therapy</keyword>
  <keyword>Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

